ArticleFrontiers in cellular and infection microbiology2026
Longitudinal assessment of MPXV-specific IgG avidity in patients with Mpox infection.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Monkeypox virus (MPXV) infection induces robust humoral immune responses; however, the kinetics of IgG avidity maturation following natural infection remain poorly characterized. Since IgG avidity reflects antibody affinity maturation over time, its evaluation may provide additional information for the interpretation of MPXV serology and infection staging. This study longitudinally assessed MPXV-specific IgG avidity in patients with confirmed mpox infection up to one year after symptom onset. Methods: Serum samples from 16 PCR-confirmed mpox patients (clade IIb) were collected within 30 days from symptom onset (T1) and at 3 (T2), 6 (T3), and 12 (T4) months of follow-up, each comprising 13 samples. Anti-MPXV (clade IIb) IgG titers and avidity indices (AI) were evaluated using an in-house indirect immunofluorescence assay (iIFA) performed with and without 4.5 M urea treatment. Neutralizing antibodies (nAbs) were measured by plaque reduction neutralization test (PRNT Results: All patients developed detectable anti-MPXV IgG within the first month after symptom onset, followed by a progressive decline in antibody titers over time, with average reductions of 1.5-, 2.9-, and 5.8-fold at T2, T3, and T4, respectively. In contrast, IgG avidity progressively increased during follow-up. Mean AI values increased from 0.132 at T1 to 0.619, 0.653, and 0.689 at T2, T3, and T4, respectively. ROC analysis identified an AI cutoff of 0.25 capable of discriminating samples collected within 30 days from those collected at later time points with high accuracy. An inverse correlation between AI and nAbs titers was observed (Spearman's r = -0.5131, p < 0.0001), suggesting distinct temporal dynamics between antibody maturation and neutralizing activity. Discussion: These findings provide one of the first longitudinal descriptions of IgG avidity maturation following natural MPXV infection and support the potential utility of avidity assessment as a complementary serological parameter for distinguishing recent from past infection. Further studies in larger and more diverse cohorts are needed to validate these observations and better define the clinical applicability of MPXV IgG avidity testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.